<DOC>
	<DOCNO>NCT02711826</DOCNO>
	<brief_summary>The purpose study : - To see polyTregs and/or `` donor reactive '' darTregs reduce inflammation transplant kidney . - To find effect , good bad , polyTregs darTregs kidney recipient . - To find effect , good bad , take everolimus polyTregs darTregs kidney recipient .</brief_summary>
	<brief_title>Treg Therapy Subclinical Inflammation Kidney Transplantation</brief_title>
	<detailed_description>Inflammation occur body 's defense system recognize foreign object ( transplanted kidney ) , respond send white blood cell attack foreign object . These cell substance produce damage transplant kidney . There currently standard treatment inflammation kidney ; transplant center treat inflammation . Rejection severe form inflammation injury . Both inflammation rejection diagnose look piece kidney ( kidney biopsy ) microscope . Kidneys inflammation and/or rejection work well last long kidney without injury . People transplant take immunosuppressive drug ( IS ) prevent inflammation rejection . Although kidney transplant recipient usually well first five year transplant , transplant researcher interested find way prevent inflammation rejection without IS , low dos IS order avoid side effect . While white blood cell cause inflammation , type white blood cell , call T regulatory cell ( Tregs ) , control inflammation . Tregs may important role control prevent inflammation rejection . A person 's Tregs grown laboratory increase number ( polyTreg ) . These Tregs give back needle place vein ( IV ) . Researchers expose transplant recipient 's Tregs donor 's cell , result Tregs recognize donor . These call donor reactive Tregs ( darTreg ) . Both polyTregs darTreg , give recipient , might reduce inflammation transplant kidney . However , effect yet show . The darTregs thought effective might able help body specifically recognize accept donate kidney . This one first clinical trial use darTregs . One IS drug use kidney transplant Everolimus . Everolimus show help Tregs survive good type IS drug . This randomized open‐label trial determine safety efficacy single dose autologous polyTregs darTregs renal transplant recipient subclinical inflammation ( SCI ) 6 month post‐transplant allograft protocol biopsy compare control patient treat CNI‐based immunosuppression . The efficacy Treg therapy assess reduction graft inflammation biopsy perform 7 month study group allocation compare eligibility biopsy .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Individuals meet follow criterion eligible enrollment study participant : 1 . Subject must able understand provide informed consent ; 2 . Recipients non Human Leukocyte Antigen ( HLA ) identical live renal transplant ; 3 . Living donor able willing 100 ml blood draw Treg manufacture ( darTreg group ) ; 4 . Protocol renal allograft biopsy 6 month ( ± 6 week ) transplantation Banff i1 and/or ti1 concomitant score t0 , t1 , t2 t3 ; Banff i2 and/or ti2 concomitant score t0 t1 ; without v &gt; 0 , [ ptc + g ] ≥2 , C4d &gt; 1 ( immunofluorescence , IF ) , C4d &gt; 0 ( immunohistochemistry , IHC ) ; confirm central pathologist . 5. eGFR ≥35 ml/min time study entry ; 6 . Maintenance immunosuppression consist tacrolimus , MMF/MPA ( ≥1000 mg/720 mg daily ) ± prednisone ( ≤10 mg/day ) ; 7 . Positive EpsteinBarr Virus ( EBV ) serology time study entry ; 8 . Current immunization include TdAP , hepatitis B , pneumococcal seasonal influenza vaccine time study entry , complete less 5 day prior enrollment ; 9 . Documented negative purified protein derivative ( PPD ) test within 1 year prior enrollment ; negative interferongamma release assay test PPD test available ; 10 . Women childbearing potential must review Mycophenolate REMS negative pregnancy test upon study entry ; 11 . Female subject childbearing potential , must agree use FDA approve method birth control duration study ; subject must consult physician determine suitable method ( ) great 80 % effective ( http : //www.fda.gov/birthcontrol ) . Treg Infusion 1 . Individuals randomize polyTreg darTreg group continue meet enrollment criterion . mTOR Conversion Individuals meet criterion eligible mTOR conversion : 1 . Received either polyTreg darTregs infusion ; 2 . Inflammatory load 2 week postinfusion biopsy decrease ≥50 % relative baseline biopsy , confirmed central pathologist . Individuals meet criterion eligible enrollment study participant : 1 . Inability unwillingness participant give write informed consent comply study protocol ; 2 . History malignancy ; except adequately treat basal cell carcinoma ; 3 . History graft loss acute rejection within 1 year previous transplant ; 4 . History transplant renal artery stenosis ; 5 . History cellular rejection precede 6 month prior enrollment respond steroid and/or subsequent creatinine treatment rejection great 15 % baseline ; 6 . Known hypersensitivity mTOR inhibitor contraindication everolimus ( include history wound heal complication ) ; 7 . Any chronic illness require uninterrupted anticoagulation kidney transplantation ; 8 . HLADR match donor locus ; 9 . Posttransplant DSA &gt; 5000 MFI posttransplant treatment IVIg DSA . Enrolled subject posttransplant DSA &gt; 2000 MFI eligible mTOR conversion . 10 . Positive HIV 1 HIV 2 serology prior transplantation ; 11 . Positive Hepatitis C virus ( HCV ) Ab serology positive HBSAg prior transplantation ; 12 . Proteinuria urine pr/cr &gt; 0.5 g/g ; 13 . Any condition require chronic use corticosteroid &gt; 10mg/day time study entry ; 14 . Active infection time study entry ; 15 . Serum BK virus &gt; 1,000 copies/ml Polymerase Chain Reaction ( PCR ) time study entry ; 16 . Hematocrit &lt; 27 % ; White Blood Cell ( WBC ) count &lt; 3,000/μL ; Absolute Neutrophil Count ( ANC ) &lt; 1,500/μL ; lymphocyte count &lt; 800/μL ; platelet count &lt; 100,000/μL time study entry ; 17 . Participation study investigational drug regimen precede year ; 18 . Any condition prior treatment , opinion investigator , precludes study participation . 19 . Unable provide adequate biopsy specimen ( paraffin embed formalin fix ) 6 month posttransplant biopsy quantitative analysis . Treg Infusion Individuals randomize polyTreg darTreg group meet criterion eligible Treg infusion : 1 . Detectable circulate EBV CMV DNA day blood collection Treg manufacture ; 2 . Received vaccination within 2 day prior blood collection Treg manufacture ; 3 . Unacceptable Treg product ; 4 . Positive pregnancy test woman child bear potential . mTOR Conversion 1 . Posttransplant DonorSpecific Antibodies ( DSA ) &gt; 2000 mean florescence intensity ( MFI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>graft inflammation</keyword>
	<keyword>Treg</keyword>
	<keyword>polyclonally expand Tregs ( polyTregs )</keyword>
	<keyword>darTregs</keyword>
	<keyword>calcineurin inhibitor ( CNIs )</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>